Akèy › Miasteni grav › Michigan
Etid klinik pou Miasteni grav nan Michigan
12 etid pou Miasteni grav ap chèche patisipan nan sit nan Michigan.
Vil nan Michigan
Tèks ofisyèl etid la (Anglè)
Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis
- Henry Ford Hospital, Detroit
Ap rekriteFaz 3
Laj 18 a 74 · Tout sèks · Mizajou Sep 25, 2026 · NCT07217587ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis
- Henry Ford Health System, Detroit
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2026 · NCT07294170ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod
- Henry Ford Health Systems, Detroit
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2026 · NCT07284420A Study to Evaluate the Efficacy and Safety of Maintenance Ublituximab Following Induction With Efgartigimod Administration in Participants With Myasthenia Gravis (MG)
- TG Therapeutics Investigational Trial Site, Farmington Hills
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07673744A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders
- TG Therapeutics Investigational Trial Site, Ann Arbor
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 9, 2026 · NCT06680037Study of Aritinercept in Patients With Generalized Myasthenia Gravis
- Aurinia Investigational Site, Dearborn
- Aurinia Investigational Site, Flint
Ap rekriteFaz 1/2
Laj 18 a 85 · Tout sèks · Mizajou Aug 3, 2026 · NCT07596901A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis
- C.S. Mott Children's Hospital, Ann Arbor
Ap rekriteFaz 2/3
Laj 2 a 17 · Tout sèks · Mizajou Jul 31, 2026 · NCT05265273Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
- Site Number - 1026, Detroit
- Site Number - 1005, East Lansing
Ap rekriteFaz 3
Laj 18 a 80 · Tout sèks · Mizajou Jul 30, 2026 · NCT07039916A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)
- Michigan State University Clinical Center, East Lansing
- Trinity Health - Grand Rapids Hospital, Grand Rapids
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Jun 18, 2026 · NCT06456580A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases
- Karmanos Cancer Institute, Detroit
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Feb 25, 2026 · NCT06626919Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs)
- Clinical Trial Site, Lansing
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Feb 18, 2026 · NCT04202341A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa
- Henry Ford Health System, Detroit
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Feb 17, 2026 · NCT06298565Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.